VEGFA and neoplasm: Endostatin, a definitive endogenous angiogenesis inhibitor, inhibits the binding of VEGF to endothelial cells by adhering to integrin, heparin sulfate, and nucleolin receptor on endothelial cells, which results in suppression of tumor cell proliferation and angiogenesis.61Endostatin along with chemotherapy was efficient in the treatment of head and neck squamous cell carcinoma.62